

Wyeth

Q-5

September 1, 2009

RECEIVED
REGION I
2009 SEP -2 AM 10:44

BY OVERNIGHT DELIVERY SERVICE
WITH CONFIRMATION OF DELIVERY

Licensing Assistance Team
Division of Nuclear Materials Safety
United States Nuclear Regulatory Commission, Region I
475 Allendale Road
King of Prussia, Pennsylvania 19406-1415

ATTN: Jennifer Johansson

03030576

RE: Wyeth Pharmaceuticals Inc., d.b.a. Wyeth Research, Princeton, NJ: Materials License, #29-28210-02
Wyeth Pharmaceuticals Inc., d.b.a. Wyeth Research; New Jersey Radioactive Materials License NJSL - 10285/01/014

Dear Ms. Johansson:

Wyeth Pharmaceuticals Inc., d.b.a. Wyeth Research, ("Wyeth Pharmaceuticals") operates the above-referenced facility and is the current holder of Materials License #29-28210-02, dated March 15, 2007, in Docket No. 03030576 (the "Materials License"). Wyeth Pharmaceuticals is a subsidiary of Wyeth. On or about September 30, 2009, Wyeth is anticipated to become a subsidiary of Pfizer Inc. ("Pfizer").

Pfizer and Wyeth, on behalf of itself and Wyeth Pharmaceuticals, provide this joint notification and request for consent to the United States Nuclear Regulatory Commission ("Commission") of the pending transaction involving Pfizer and Wyeth ("Transaction").* The following information is offered in support of this submittal:

1. In the Transaction, Wagner Acquisition Corp., a wholly-owned subsidiary of Pfizer, will merge with Wyeth. Wyeth will survive as a subsidiary of Pfizer. Wyeth Pharmaceuticals, the holder of the Materials License, will continue to own

*Because of some question about whether the Transaction constitutes an indirect change of control under Section 184 of the Atomic Energy Act, 10 C.F.R. 30.41 and applicable guidance, Pfizer and Wyeth provide this joint notification and request for consent out of an abundance of caution.

REC'D IN LAT

9/1/09

144134
NRC/SS/RGNI MATERIALS-002

its properties and assets and continue to be responsible for its liabilities. In addition, Wyeth Pharmaceuticals will not change its name, and will continue its corporate existence as a subsidiary of Wyeth.

2. With respect to the licensed program, it is anticipated that there will be no changes in personnel or their duties. In addition, there are no plans to relocate the facilities in which the licensed materials are stored and used, nor to modify them. In summary, the expectation is, with respect to the licensed program, Wyeth Pharmaceuticals' management will continue after the transaction as it has beforehand.
3. No changes in the organization, location, facilities, equipment or procedures that relate to the licensed program are anticipated to occur because of the Transaction.
4. The present status of the surveillance program, as described in the December 14, 2004 application, is not expected to change.
5. All records concerning safe and effective decommissioning of the facilities identified in Item 10 of License #29-28219-02 (including documentation of surveys of ambient radiation levels and fixed and/or removable contamination, including methods and sensitivity) will remain in place with Wyeth Pharmaceuticals.
6. Pfizer will abide by all constraints, conditions, requirements and commitments to which Wyeth Pharmaceuticals is subject in connection with the licensed material and licensed program.
7. In fulfillment of Items 5 through 11 of NRC Form 313, Pfizer states that there will be no changes to Conditions 10 through 22 of License #29-28219-02, attached hereto.

In addition, Wyeth Pharmaceuticals is also the current holder of New Jersey Radioactive Materials License NJSL – 10285/01/014. Due to the August 7, 2009 expiration of the time-limited waiver of the provisions of the Energy Policy Act of 2005, and due to New Jersey's current status of not entering into an Agreement State relationship with the NRC, this notification is also intended to serve to inform NRC of the Transaction, as it is relevant to the NJSL-10285/01/014 license.

We will provide appropriate notice to you, as required, if any additional changes relating to the Materials License should arise. Please contact either of us if any of the above information is unclear or if additional information is required. Thank you for your attention to this matter.

United States Nuclear Regulatory Commission
September 1, 2009
Page 3

Sincerely,

[SIGNATURE BLOCK INTENTIONALLY LEFT BLANK.
SEE ATTACHED SIGNATURES ON FOLLOWING PAGES.]

cc: Ms. Patricia Gardner, NJDEP Bureau of Environmental Radiation
Sally R.K. Fisk, Esq., Pfizer
Mr. Richard M. Davis, Pfizer
Stephanie M. Haggerty, Esq., Wyeth
Ronald J. Schott, Esq., Wyeth
Paul Linsalata, Ph.D., CHP, Wyeth
Mary Dorman, RSO, Wyeth Princeton

United States Nuclear Regulatory Commission
September 1, 2009
Page 4


Sincerely,

Richard Ciccarelli

Richard Ciccarelli, Sr. Vice President
Wyeth Research
500 Arcola Rd
Collegeville, PA 19426
484-865-9135 (office) 484-865-6416 (fax)
Ciccarr@wyeth.com

United States Nuclear Regulatory Commission
September 1, 2009
Page 5

Sincerely,

A handwritten signature in black ink, appearing to read "Steve Brooks", written over a horizontal line.

**Steve Brooks, VP, Pfizer Global EHS
Operations
Pfizer Inc
150 E. 42nd Street, 150/2/66
New York, NY 10017
212-733-0926 (office), 646-348-8277 (fax)
steve.brooks@pfizer.com**

This is to acknowledge the receipt of your letter/application dated

9/1/09, and to inform you that the initial processing which includes an administrative review has been performed.

Notification (29-28210-02)
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 144134.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (R1)
(6-96)

Sincerely,
Licensing Assistance Team Leader